PEITC Targets EGFR to Suppress Ovarian Cancer Figure 1. PEITC suppresses the growth of ovarian tumor xenografts by inhibiting EGFR-AKT pathway. SKOV-3 tumor cells were implanted into athymic nude mice and randomized into two groups. Mice received PBS or 12 mmol PEITC by oral gavage every day until day 42. (A–i) Effect of PEITC on tumor growth. (A-ii) Tumor weight from control and treatment groups (B) Inhibition of EGFR signaling in the tumors of mice administered with PEITC. Tumors from control and treated mice were excised at day 42, lysed and analyzed by western blotting for p-EGFR (Tyr-1068), EGFR, p-AKT (Ser-473), AKT, Cl-Caspase 3 and Cl-PARP. Blots were stripped and reprobed with actin antibody to verify equal protein loading. Each lane represents a different tumor sample. (C) Densitometric quantitation of western blotting represented above. The differences between the groups were compared by student’s t-test. Statistical tests were two sided. *p,0.05 when compared to control. doi:10.1371/journal.pone.0043577.g001 PLOS ONE | www.plosone.org 2 August 2012 | Volume 7 | Issue 8 | e43577